What is LRMR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.28B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LRMR?

P/E (TTM) is n/a and 52-week range is $2.61 to $6.42 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LRMR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LRMR?

The company profile lists net income (TTM) near $-206M, EPS (TTM) near $-1.99 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Larimar Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bala Cynwyd, Pennsylvania, US, 103.9M shares outstanding, ISIN US5171251003 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Larimar Therapeutics Inc

$LRMR

Health Care · Biotechnology

IR Run Scenarios

$2.67

-1.11%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Employees

Website

larimartx.com/

IPO

2014-06-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)